Rapid, Field Deployable COVID-19 Testing

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    -99
  • Known Financial Commitments (USD)

    $0
  • Funder

    University of Minnesota
  • Principal Investigator

    PhD. Mark Osborn
  • Research Location

    United States of America
  • Lead Research Institution

    Medical School, University of Minnesota
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The current lack of expeditious testing for COVID-19 represents a critical diagnostic and therapeutic gap. This study led by Mark Osborn, PhD, assistant professor of pediatrics, will determine if a rapid, point of care system operative in his lab can be rapidly adapted and deployed as part of a field-based COVID-19 diagnostic platform that does not require specialized techniques or equipment. "Our assay will be designed to rapidly test for COVID-19 and then further distinguish between COVID-19 Type I and Type II," said Osborn. Type II COVID is believed to be more infectious, so the ability to discriminate between Types I and II can not only help prioritize patients for urgent care, it can provide important information for epidemiologists and policy makers. "Using rapid nucleic acid isolation, amplification, and detection with our design will give results in one hour. This streamlined approach will help in easing the current test backlog and will be a valuable public health resource, especially in areas where advanced medical and diagnostic infrastructure is not present," said Osborn.